TWI256950B - Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them - Google Patents

Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them

Info

Publication number
TWI256950B
TWI256950B TW089112238A TW89112238A TWI256950B TW I256950 B TWI256950 B TW I256950B TW 089112238 A TW089112238 A TW 089112238A TW 89112238 A TW89112238 A TW 89112238A TW I256950 B TWI256950 B TW I256950B
Authority
TW
Taiwan
Prior art keywords
benzenecarboxamides
indanyl
medicament
substituted
processes
Prior art date
Application number
TW089112238A
Other languages
English (en)
Chinese (zh)
Inventor
Joachim Brendel
Uwe Gerlach
Heinrich Steude
Hans-Jochen Lang
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of TWI256950B publication Critical patent/TWI256950B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/26—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
TW089112238A 1999-06-25 2000-06-22 Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them TWI256950B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929076A DE19929076A1 (de) 1999-06-25 1999-06-25 Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
TWI256950B true TWI256950B (en) 2006-06-21

Family

ID=7912468

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089112238A TWI256950B (en) 1999-06-25 2000-06-22 Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them

Country Status (31)

Country Link
US (1) US6221866B1 (enExample)
EP (1) EP1194403B1 (enExample)
JP (1) JP4527918B2 (enExample)
KR (1) KR20020023962A (enExample)
CN (1) CN1157372C (enExample)
AR (1) AR024443A1 (enExample)
AT (1) ATE248811T1 (enExample)
AU (1) AU771601B2 (enExample)
BR (1) BR0011938A (enExample)
CA (1) CA2377087A1 (enExample)
CZ (1) CZ20014523A3 (enExample)
DE (2) DE19929076A1 (enExample)
DK (1) DK1194403T3 (enExample)
EE (1) EE04464B1 (enExample)
ES (1) ES2200886T3 (enExample)
HK (1) HK1047575B (enExample)
HU (1) HUP0201711A3 (enExample)
IL (1) IL147220A0 (enExample)
MX (1) MXPA01012281A (enExample)
NO (1) NO20015816L (enExample)
NZ (1) NZ516347A (enExample)
PL (1) PL352985A1 (enExample)
PT (1) PT1194403E (enExample)
RU (1) RU2238934C2 (enExample)
SI (1) SI1194403T1 (enExample)
SK (1) SK19092001A3 (enExample)
TR (1) TR200103701T2 (enExample)
TW (1) TWI256950B (enExample)
WO (1) WO2001000573A1 (enExample)
YU (1) YU88801A (enExample)
ZA (1) ZA200109732B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6970362B1 (en) 2000-07-31 2005-11-29 Intel Corporation Electronic assemblies and systems comprising interposer with embedded capacitors
US6775150B1 (en) 2000-08-30 2004-08-10 Intel Corporation Electronic assembly comprising ceramic/organic hybrid substrate with embedded capacitors and methods of manufacture
AU2001294606A1 (en) 2000-09-20 2002-04-02 Brad A. Acker Substituted azepino(4,5b)indoline derivatives
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) * 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US7595322B2 (en) 2003-03-27 2009-09-29 Cytokinetics, Inc. Heterocyclic sulfonamides as modulators of cardiac sarcomeres
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US7368582B2 (en) 2003-10-17 2008-05-06 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
WO2007023775A1 (ja) * 2005-08-23 2007-03-01 Astellas Pharma Inc. 心房細動治療剤
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
AU2007245891B2 (en) * 2006-04-27 2012-10-18 Sanofi-Aventis Deutschland Gmbh Inhibitors of the TASK-1 and TASK-3 ion channel
CA2657247A1 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
BRPI0718515A2 (pt) 2006-09-25 2013-11-19 Boehringer Ingelheim Int Compostos que modulam o receptor cb2
WO2008098025A1 (en) * 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Arylsulfonamide compounds which modulate the cb2 receptor
JP4891111B2 (ja) * 2007-02-16 2012-03-07 富士フイルム株式会社 ズームレンズ
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
US8546563B2 (en) * 2007-11-07 2013-10-01 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CA2730037A1 (en) * 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CA2737639A1 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
EP2480544A1 (en) * 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (enExample) 2011-07-01 2018-04-28
CA2862670A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
WO2020227097A1 (en) * 2019-05-03 2020-11-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2023211855A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a thiophene core and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234944A (en) 1986-08-21 1993-08-10 Roussel Uclaf Novel indanes
EP0258096B1 (fr) 1986-08-21 1992-09-09 Roussel-Uclaf Dérivés de l'indane, leur procédé de préparation, leur application à titre de médicaments, les compositions pharmaceutiques les renfermant et les intermédiaires obtenus
DK626889A (da) 1988-12-16 1990-06-17 Roussel Uclaf Indanderivater, deres fremstilling samt laegemidler med indhold deraf
US5348971A (en) 1988-12-16 1994-09-20 Roussel Uclaf Indanes useful as analgesics
RU2043337C1 (ru) * 1990-07-20 1995-09-10 Институт биохимии Литовской АН Способ получения 5-аргиниламинонафталин-1-сульфамидов
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
HU225986B1 (en) * 1994-01-10 2008-02-28 Teva Pharma Use of 1-aminoindan derivatives for preparing pharmaceutical compns. and 1-aminoindan derivatives
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DE19707656A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Sulfonamid-substituierte anellierte 7-Ring-Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
JP2001513526A (ja) * 1997-08-05 2001-09-04 アメリカン・ホーム・プロダクツ・コーポレイション アントラニル酸類似体
DE19749453A1 (de) 1997-11-10 1999-05-12 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte anellierte 5-Ring-Verbindungen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
IL147220A0 (en) 2002-08-14
TR200103701T2 (tr) 2002-05-21
NO20015816D0 (no) 2001-11-29
EP1194403A1 (de) 2002-04-10
HUP0201711A3 (en) 2005-05-30
AU771601B2 (en) 2004-03-25
PL352985A1 (en) 2003-09-22
MXPA01012281A (es) 2002-07-30
CA2377087A1 (en) 2001-01-04
ZA200109732B (en) 2002-08-30
EP1194403B1 (de) 2003-09-03
RU2238934C2 (ru) 2004-10-27
EE200100684A (et) 2003-04-15
KR20020023962A (ko) 2002-03-29
ATE248811T1 (de) 2003-09-15
DE50003555D1 (de) 2003-10-09
CN1358172A (zh) 2002-07-10
DE19929076A1 (de) 2000-12-28
DK1194403T3 (da) 2003-12-08
SI1194403T1 (en) 2003-12-31
AR024443A1 (es) 2002-10-02
NZ516347A (en) 2004-01-30
NO20015816L (no) 2001-11-29
HK1047575B (zh) 2004-12-31
PT1194403E (pt) 2004-01-30
HK1047575A1 (en) 2003-02-28
JP2003503385A (ja) 2003-01-28
US6221866B1 (en) 2001-04-24
WO2001000573A1 (de) 2001-01-04
ES2200886T3 (es) 2004-03-16
JP4527918B2 (ja) 2010-08-18
CZ20014523A3 (cs) 2002-04-17
YU88801A (sh) 2004-09-03
EE04464B1 (et) 2005-04-15
CN1157372C (zh) 2004-07-14
AU5531800A (en) 2001-01-31
BR0011938A (pt) 2002-03-19
SK19092001A3 (sk) 2002-06-04
HUP0201711A2 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
TWI256950B (en) Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them
MY143521A (en) Anthranilamides and methods of their use
MY138341A (en) Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use
HRP20030448A2 (en) Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
YU24402A (sh) 2'-supstituisani 1,1'-bifenil-2-karbonamidi, postupak za njihovu proizvodnju, njihova primena kao leka kao i farmaceutski preparati koji sadrže ta jedinjenja
YU42503A (sh) Arilovani furan-1 tiofen-amidi-karbonske kiseline sa blokirajućim dejstvom kalijumovog kanala
AR031430A1 (es) Compuestos de bisarilo orto, meta-sustituidos, procedimientos para su preparacion, su utilizacion como medicamento como tambien los preparados farmaceuticos que los contienen
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
CA2178760A1 (en) HIV Protease Inhibitors
AU2108500A (en) Galenic formulation containing biotin
AU1727797A (en) Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
IL188092A0 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
BR0206791A (pt) Composto, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritmia, e, processo para a preparação de um composto
BR0016678A (pt) Composto, formulação farmacêutica, uso de um composto, método para profilaxia ou tratamento de uma arritmia, e, processo para preparação de um composto
MX9603300A (es) Derivados de la 4-sulfonilbenzoilguanidina o la 4-sulfinilbenzoilguanidina.
SE0003795D0 (sv) Pharmaceutically useful compounds
JP2001048801A5 (ja) 経口用メラニン生成抑制組成物及び美白効果を有する食品
MXPA05009763A (es) 2-(butil-1-sulfonilamino)-n-[1 (r)-(6-metoxipiridin-3-il) propil] benzamida, su uso en forma de un farmaco y preparaciones farmaceuticas que contienen a dicho compuesto.
WO2000002877A3 (en) New pharmaceutically active compounds
SE9902268D0 (sv) Pharmaceutically active compounds
AU4302996A (en) Uracil derivatives
SE9902270D0 (sv) Pharmaceutically active compounds
SE9902269D0 (sv) Pharmaceutically active compounds

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees